Perrigo Co. has been cleared by the Food and Drug Administration to market repaglinide tablets in strengths of 1 mg and 2 mg.


Perrigo, repaglinide tablets, Prandin tablets, Prandin generic, type 2 diabetes, Novo Nordisk






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Perrigo releases Prandin generic

January 27th, 2014

DUBLIN, Ireland – Perrigo Co. has been cleared by the Food and Drug Administration to market repaglinide tablets in strengths of 1 mg and 2 mg.

The company said Friday that its product is a generic equivalent of Novo Nordisk's Prandin tablets (repaglinide).

Perrigo has begun shipping the new Prandin generic product. The company previously launched the 0.5-mg strength of repaglinide tablets last year.

Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The medication has annual sales of approximately $250 million, according to data from Symphony Health Solutions reported by Perrigo.

Advertisement